|
|
Patient-specific therapy of glioblastoma using lightly-labeled [14C]-temozolomide
|
1R43CA134184-01
|
$102,900
|
$102,900
|
Arjomand, Ali
|
ACCIUM BIOSCIENCES, INC.
|
|
|
RADIATION THERAPY ONCOLOGY GROUP
|
3U10CA021661-32S2
|
$9,611,397
|
$4,709,585
|
CURRAN, WALTER
|
AMERICAN COLLEGE OF RADIOLOGY
|
|
|
RADIATION THERAPY ONCOLOGY GROUP
|
3U10CA021661-32S3
|
$3,952
|
$1,936
|
CURRAN, WALTER
|
AMERICAN COLLEGE OF RADIOLOGY
|
|
|
RADIATION THERAPY ONCOLOGY GROUP
|
3U10CA021661-32S4
|
$80,640
|
$39,514
|
CURRAN, WALTER
|
AMERICAN COLLEGE OF RADIOLOGY
|
|
|
Community Clinical Oncology Program Research Base
|
3U10CA037422-21S1
|
$27,801
|
$13,622
|
CURRAN, WALTER
|
AMERICAN COLLEGE OF RADIOLOGY
|
|
|
Community Clinical Oncology Program Research Base
|
5U10CA037422-21
|
$1,665,362
|
$816,027
|
CURRAN, WALTER
|
AMERICAN COLLEGE OF RADIOLOGY
|
|
|
Radiation Therapy Oncology Group-Statistical Center
|
3U10CA032115-26S1
|
$1,010,519
|
$495,154
|
Sadek, Ramses
|
AMERICAN COLLEGE OF RADIOLOGY
|
|
|
QUALITY RESEARCH IN RADIATION ONCOLOGY: ACR PCS
|
5R01CA065435-10
|
$740,839
|
$259,294
|
WILSON, JESSE
|
AMERICAN COLLEGE OF RADIOLOGY
|
|
|
Targeted Ceramic Nanovectors for Simultaneous Therapy and Imaging of Cancer
|
1R21CA133618-01
|
$231,517
|
$115,759
|
DEY, SANDWIP
|
ARIZONA STATE UNIVERSITY-TEMPE CAMPUS
|
|
|
Microfluidics-Based Platform for Screening Combinatorial Drug Treatments
|
1R21CA131891-01A1
|
$210,715
|
$210,715
|
Rege, Kaushal
|
ARIZONA STATE UNIVERSITY-TEMPE CAMPUS
|
|
|
Drug Delivery Carriers Targeted to Breast Tumor by Fusion Phage Proteins
|
5R01CA125063-02
|
$373,539
|
$373,539
|
PETRENKO, VALERY
|
AUBURN UNIVERSITY AT AUBURN
|
|
|
Bay Area Tumor Institute CCOP
|
5U10CA045461-19
|
$481,201
|
$211,728
|
Feusner, James
|
BAY AREA TUMOR INSTITUTE
|
|
|
NSABP Participating Sites
|
5U10CA118735-03
|
$66,231
|
$42,388
|
CHANG, JENNY
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Proteosome Inhibition Therapy for Hematologic Malignancy
|
5K23CA113775-03
|
$134,015
|
$134,015
|
HORTON, TERZAH
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
RNAi-Based Therapy of Hepatocellular Carcinoma
|
5R01CA109574-04
|
$224,720
|
$224,720
|
LI, KAIYI
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Translational Research in Breast Cancer
|
2P50CA058183-14
|
$2,300,000
|
$276,000
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-02S1
|
$117,286
|
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-02S1
|
$117,286
|
$1,173
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Baylor College of Medicine Cancer Center
|
5P30CA125123-02
|
$1,515,000
|
$15,150
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Pediatric Clinical Oncology Research Training Program
|
5K12CA090433-07
|
$707,872
|
$141,574
|
Poplack, David
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Improving the Efficacy of Dendritic Cell Vaccines
|
5P01CA084512-07
|
$985,145
|
$295,544
|
Banchereau, Jacques
|
BAYLOR RESEARCH INSTITUTE
|
|
|
A Pull-Push Strategy for Lymphoma Immunotherapy
|
5K08CA105064-05
|
$128,547
|
$64,274
|
Song, Wenru
|
BAYLOR RESEARCH INSTITUTE
|
|
|
Virginia Mason Community Clinical Oncology Program
|
5U10CA035192-25
|
$453,250
|
$181,300
|
Vuky, Jacqueline
|
BENAROYA RESEARCH INST AT VIRGINIA MASON
|
|
|
Eastern Cooperative Oncology Group
|
5U10CA080775-10
|
$128,678
|
$128,678
|
ATKINS, MICHAEL
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
|
Enhanced RF Tumor Ablation with Liposomal Chemotherapy
|
5R01CA112533-05
|
$382,713
|
$382,713
|
GOLDBERG, S.
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
|
Control of Protein Translation in Cancer Pathogenesis
|
7U01CA084292-10
|
$697,531
|
$697,531
|
PANDOLFI, PIER PAOLO
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
|
Rectifying defects in tumor vasculature to improve chemo- and radiation therapies
|
1R01CA129339-01A1
|
$352,750
|
$352,750
|
SENGER, DONALD
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
|
Circulating Tumor Cells in Non-Small Cell Lung Cancer
|
5R01CA125653-02
|
$337,278
|
$337,278
|
Nieva, Jorge
|
BILLINGS CLINIC FOUNDATION
|
|
|
SBIR TOPIC 241 - TARGETED NANOPARTICLES FOR PROSTATE CANCER THERAPY
|
N43CO700060-000
|
|
$0
|
HRKACH, JEFFREY
|
BIND BIOSCIENCES, INC.
|
|
|
Cyclic AMP-mediated apoptosis in lymphoid malignancies
|
5R01CA106705-04
|
$241,199
|
$241,199
|
LERNER, ADAM
|
BOSTON MEDICAL CENTER
|
|
|
Analysis of AND-34 in human breast cancer
|
5R01CA114094-04
|
$229,749
|
$114,875
|
LERNER, ADAM
|
BOSTON MEDICAL CENTER
|
|
|
Long-term Survivorship in Older Women with Early Stage Breast Cancer
|
2R01CA093772-05A2
|
$1,115,875
|
$557,938
|
SILLIMAN, REBECCA
|
BOSTON MEDICAL CENTER
|
|
|
Cancer Control in Older Adults
|
5K05CA092395-08
|
$148,568
|
$148,568
|
SILLIMAN, REBECCA
|
BOSTON MEDICAL CENTER
|
|
|
Hepatic Metabolism of Anti-cancer Drugs
|
3R01CA049248-19S1
|
$50,877
|
$50,877
|
WAXMAN, DAVID
|
BOSTON UNIVERSITY
|
|
|
Hepatic Metabolism of Anti-cancer Drugs
|
5R01CA049248-19
|
$275,637
|
$275,637
|
WAXMAN, DAVID
|
BOSTON UNIVERSITY
|
|
|
Ras Oncoprotein-Targeted Therapy for Cancer
|
3R01CA112102-04S1
|
$54,979
|
$54,979
|
Faller, Douglas
|
BOSTON UNIVERSITY MEDICAL CAMPUS
|
|
|
Ras Oncoprotein-Targeted Therapy for Cancer
|
5R01CA112102-04
|
$302,435
|
$302,435
|
Faller, Douglas
|
BOSTON UNIVERSITY MEDICAL CAMPUS
|
|
|
Modification of tamoxifen effectiveness by gene polymorphisms and other drugs
|
5R01CA118708-03
|
$234,985
|
$117,493
|
LASH, TIMOTHY
|
BOSTON UNIVERSITY MEDICAL CAMPUS
|
|
|
The fuel sensing enzyme AMPK in the pathogenesis of prostate cancer
|
5R01CA118918-03
|
$224,058
|
$224,058
|
Luo, Zhijun
|
BOSTON UNIVERSITY MEDICAL CAMPUS
|
|
|
Novel vitamin D analog for kidney cancer
|
1R21CA127629-01A2
|
$182,813
|
$182,813
|
RAY, RAHUL
|
BOSTON UNIVERSITY MEDICAL CAMPUS
|
|
|
Heat shock proteins in cancer and signaling
|
5R01CA081244-10
|
$343,115
|
$68,623
|
SHERMAN, MICHAEL
|
BOSTON UNIVERSITY MEDICAL CAMPUS
|
|
|
Effects of mTOR inhibitors on multiple myeloma tumors
|
5K01CA111623-04
|
$149,580
|
$149,580
|
Frost, Patrick
|
BRENTWOOD BIOMEDICAL RESEARCH INSTITUTE
|
|
|
Use of CCI-779 in multiple myeloma
|
1R21CA121464-01A2
|
$319,950
|
$319,950
|
LICHTENSTEIN, ALAN
|
BRENTWOOD BIOMEDICAL RESEARCH INSTITUTE
|
|
|
Curcumin suppression of head and neck cancer
|
5R21CA116826-02
|
$123,600
|
$61,800
|
WANG, MARILENE
|
BRENTWOOD BIOMEDICAL RESEARCH INSTITUTE
|
|
|
Signal Transduction Pathways in Glioblastoma
|
5R01CA108633-04
|
$445,200
|
$222,600
|
CHAKRAVARTI, ARNAB
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
|
Dana-Farber/Harvard Cancer Center Ovarian Cancer SPORE
|
5P50CA105009-05
|
$2,176,201
|
$435,240
|
CRAMER, DANIEL
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
|
Multicenter clinical trials for TSC & related disorders
|
5R01CA107164-04
|
$181,066
|
$181,066
|
DABORA, SANDRA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
|
SPORE in Skin Cancer
|
2P50CA093683-06A2
|
$2,300,000
|
$460,000
|
KUPPER, THOMAS
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
|
Hormones, hormone-related genes, and colorectal cancer
|
5K07CA112529-04
|
$106,649
|
$106,649
|
Lin, Jennifer
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
|
Biomarkers and Therapeutic Targets in Pancreatic Cancer
|
5R01CA114103-04
|
$287,037
|
$114,815
|
WHANG, EDWARD
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Total relevant funding to Chemotherapy for this search: $531,693,966
|
